Addition of Intraperitoneal Cisplatin and Etoposide to First-Line Chemotherapy for Advanced Ovarian Cancer: A Randomised, Phase 2 Trial

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-018-0036-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Treatment of Metastatic Germ Cell Tumors With Etoposide and Cisplatin as First Line Chemotherapy

Japanese Journal of Urology
Urology
2002English

PROFAST: ERAS in Advanced Ovarian Cancer, a Randomised Trial

Clinical Nutrition ESPEN
EndocrinologyNutritionMetabolismDieteticsDiabetes
2016English

Neoadjuvant, Adjuvant and Long-Term Intravenous/Intraperitoneal Chemotherapy, Hyperthermic Intraperitoneal Chemotherapy, Early Postoperative Intraperitoneal Chemotherapy for Ovarian Cancer

Journal of Peritoneum (and other serosal surfaces)
2017English

Is Peritonectomy and Hyperthermic Intraperitoneal Chemotherapy a New Standard of Treatment for Advanced Epithelial Ovarian Cancer?

Australian and New Zealand Journal of Obstetrics and Gynaecology
MedicineGynecologyObstetrics
2019English

Hyperthermic Intraperitoneal Chemotherapy Does Not Improve Survival in Advanced Ovarian Cancer

Cancer
Cancer ResearchOncology
2019English

G08Feasibility and Tolerability of Intraperitoneal Chemotherapy in Ovarian Cancer

Annals of Oncology
MedicineOncologyHematology
2016English

Randomized Phase III Trial of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients With Extensive-Disease Small Cell Lung Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2019English

Phase II Study of Second-Line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma

Anticancer Research
MedicineCancer ResearchOncology
2020English

Intraperitoneal Chemotherapy in Ovarian Cancer: A Review of Tolerance and Efficacy

Cancer Management and Research
Oncology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy